Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2015
Number of items: 4.

2015

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

This list was generated on Tue Apr 23 15:59:13 2024 CEST.